Lifeward Ltd. (LFWD) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Lifeward Ltd. is a medical device company specializing in physical rehabilitation and recovery solutions, including the ReWalk exoskeleton for spinal cord injury (SCI) patients, AlterG Anti-Gravity systems, and the ReStore exo-suit. The company operates as a single reporting unit with primary markets in the United States and Europe.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $5.72 million | $10.76 million | $11.99 million |
| Gross Profit | $2.51 million (43.9% margin) | $4.63 million (43.1% margin) | $4.15 million (34.6% margin) |
| Operating Loss | $(6.56) million | $(11.42) million | $(10.95) million |
| Net Loss | $(6.56) million | $(11.40) million | $(10.58) million |
| Cash & Equivalents | $5.14 million (as of June 30, 2025) | ||
| Operating Cash Flow | $(9.43) million used (YTD 2025) | ||
| Financing Cash Flow | $7.78 million provided (YTD 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 14.7% in Q2 and 10.3% YTD compared to 2024. This was primarily due to the absence of one-time Medicare-related revenue recognized in Q2 2024 and lower MyoCycle sales volume.
- Margin Improvement: Gross margin improved to 43.1% YTD (vs. 34.6% in 2024), driven by the closure of the Fremont manufacturing facility, the transition of AlterG production to a contract manufacturer, and the recent shift of ReWalk production in-house.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $2.78 million in Q2 2025. This was triggered by a sustained decline in the company's stock price, causing market capitalization to fall below the carrying value of the reporting unit.
- Cost Reductions: Operating expenses decreased due to reduced R&D spending (completion of ReWalk 7 and AlterG NEO development) and lower sales/marketing costs (reduced consultant fees and amortization of intangible assets).
- Equity Raises: The company raised capital through a Registered Direct Offering in January 2025, an At-The-Market (ATM) program, and a Public Offering in June 2025, resulting in net financing proceeds of $7.78 million YTD.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern for the next 12 months. Cash resources are estimated to fund operations only into the fourth quarter of 2025. Additional financing is required to sustain operations.
- Nasdaq Compliance: On August 5, 2025, the company received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive days. The company has 180 days (until February 2, 2026) to regain compliance or face potential delisting.
- Operational Highlights:
- Successfully transitioned ReWalk manufacturing in-house, terminating the agreement with Sanmina Corporation.
- Received FDA clearance for the ReWalk 7 exoskeleton in April 2025.
- Secured a favorable Administrative Law Judge ruling establishing Medicare coverage for the ReWalk Personal Exoskeleton as "reasonable and necessary."
- Appointed Mark Grant as President and CEO and Almog Adar as CFO.
- Risks: Key risks include the inability to secure additional capital, potential delisting from Nasdaq, challenges in scaling in-house manufacturing, and reliance on third-party payors for reimbursement.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for securing additional capital, as current cash ($5.1M) is projected to last only until Q4 2025.
- Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid Nasdaq delisting by February 2026.
- Manufacturing Transition: Assess the operational stability and cost savings realized from the in-house ReWalk manufacturing transition following the termination of the Sanmina contract.
- Reimbursement Progress: Track the volume of Medicare and commercial insurance claims processed following the recent ALJ ruling and the CorLife partnership.
- Dilution Impact: Review the impact of recent equity offerings (January and June 2025) and outstanding warrants on shareholder dilution.